DNA intercalators in cancer therapy: organic and inorganic drugs and their spectroscopic tools of analysis

N.J. Wheate, J.G. Collins, S. Kemp, J.R. Aldrich-Wright, C.R. Brodie

Research output: Contribution to journalArticle

155 Citations (Scopus)

Abstract

Since the discovery of the DNA intercalation process by Lerman in 1961 thousands of organic, inorganic octahedral (particularly ruthenium(II) and rhodium(III)) and square-planar (particularly platinum(II)) compounds have been developed as potential anticancer agents and diagnostic agents. The design and synthesis of new drugs is focused on bis-intercalators which have two intercalating groups linked via a variety of ligands, and synergistic drugs, which combine the anticancer properties of intercalation with other functionalities, such as covalent binding or boron-cages (for radiation therapy). Advances in spectroscopic techniques mean that the process of DNA intercalation can be examined in far greater detail than ever before, yielding important information on structure-activity relationships. In this review we examine the history and development of DNA intercalators as anticancer agents and advances in the analysis of DNA-drug interactions.
LanguageEnglish
Pages627-648
Number of pages21
JournalMini-Reviews in Medicinal Chemistry
Volume7
Issue number6
DOIs
Publication statusPublished - Jun 2007

Fingerprint

Intercalating Agents
DNA
Pharmaceutical Preparations
Antineoplastic Agents
Neoplasms
Platinum Compounds
Rhodium
Boron
Ruthenium
Therapeutics
Structure-Activity Relationship
Drug Interactions
Radiotherapy
History
Ligands

Keywords

  • DNA intercalation
  • bis-intercalation
  • synergistic
  • anticancer
  • cytotoxicity
  • spectrometry
  • review

Cite this

Wheate, N.J. ; Collins, J.G. ; Kemp, S. ; Aldrich-Wright, J.R. ; Brodie, C.R. / DNA intercalators in cancer therapy: organic and inorganic drugs and their spectroscopic tools of analysis. In: Mini-Reviews in Medicinal Chemistry. 2007 ; Vol. 7, No. 6. pp. 627-648.
@article{8e352a445b7247e49b50a8be8e670381,
title = "DNA intercalators in cancer therapy: organic and inorganic drugs and their spectroscopic tools of analysis",
abstract = "Since the discovery of the DNA intercalation process by Lerman in 1961 thousands of organic, inorganic octahedral (particularly ruthenium(II) and rhodium(III)) and square-planar (particularly platinum(II)) compounds have been developed as potential anticancer agents and diagnostic agents. The design and synthesis of new drugs is focused on bis-intercalators which have two intercalating groups linked via a variety of ligands, and synergistic drugs, which combine the anticancer properties of intercalation with other functionalities, such as covalent binding or boron-cages (for radiation therapy). Advances in spectroscopic techniques mean that the process of DNA intercalation can be examined in far greater detail than ever before, yielding important information on structure-activity relationships. In this review we examine the history and development of DNA intercalators as anticancer agents and advances in the analysis of DNA-drug interactions.",
keywords = "DNA intercalation, bis-intercalation, synergistic, anticancer, cytotoxicity, spectrometry, review",
author = "N.J. Wheate and J.G. Collins and S. Kemp and J.R. Aldrich-Wright and C.R. Brodie",
year = "2007",
month = "6",
doi = "10.2174/138955707780859413",
language = "English",
volume = "7",
pages = "627--648",
journal = "Mini-Reviews in Medicinal Chemistry",
issn = "1389-5575",
number = "6",

}

DNA intercalators in cancer therapy: organic and inorganic drugs and their spectroscopic tools of analysis. / Wheate, N.J.; Collins, J.G.; Kemp, S.; Aldrich-Wright, J.R.; Brodie, C.R.

In: Mini-Reviews in Medicinal Chemistry, Vol. 7, No. 6, 06.2007, p. 627-648.

Research output: Contribution to journalArticle

TY - JOUR

T1 - DNA intercalators in cancer therapy: organic and inorganic drugs and their spectroscopic tools of analysis

AU - Wheate, N.J.

AU - Collins, J.G.

AU - Kemp, S.

AU - Aldrich-Wright, J.R.

AU - Brodie, C.R.

PY - 2007/6

Y1 - 2007/6

N2 - Since the discovery of the DNA intercalation process by Lerman in 1961 thousands of organic, inorganic octahedral (particularly ruthenium(II) and rhodium(III)) and square-planar (particularly platinum(II)) compounds have been developed as potential anticancer agents and diagnostic agents. The design and synthesis of new drugs is focused on bis-intercalators which have two intercalating groups linked via a variety of ligands, and synergistic drugs, which combine the anticancer properties of intercalation with other functionalities, such as covalent binding or boron-cages (for radiation therapy). Advances in spectroscopic techniques mean that the process of DNA intercalation can be examined in far greater detail than ever before, yielding important information on structure-activity relationships. In this review we examine the history and development of DNA intercalators as anticancer agents and advances in the analysis of DNA-drug interactions.

AB - Since the discovery of the DNA intercalation process by Lerman in 1961 thousands of organic, inorganic octahedral (particularly ruthenium(II) and rhodium(III)) and square-planar (particularly platinum(II)) compounds have been developed as potential anticancer agents and diagnostic agents. The design and synthesis of new drugs is focused on bis-intercalators which have two intercalating groups linked via a variety of ligands, and synergistic drugs, which combine the anticancer properties of intercalation with other functionalities, such as covalent binding or boron-cages (for radiation therapy). Advances in spectroscopic techniques mean that the process of DNA intercalation can be examined in far greater detail than ever before, yielding important information on structure-activity relationships. In this review we examine the history and development of DNA intercalators as anticancer agents and advances in the analysis of DNA-drug interactions.

KW - DNA intercalation

KW - bis-intercalation

KW - synergistic

KW - anticancer

KW - cytotoxicity

KW - spectrometry

KW - review

UR - http://dx.doi.org/10.2174/138955707780859413

U2 - 10.2174/138955707780859413

DO - 10.2174/138955707780859413

M3 - Article

VL - 7

SP - 627

EP - 648

JO - Mini-Reviews in Medicinal Chemistry

T2 - Mini-Reviews in Medicinal Chemistry

JF - Mini-Reviews in Medicinal Chemistry

SN - 1389-5575

IS - 6

ER -